Related Experiment Video
Updated: Mar 10, 2026

Single-cell Transcriptomic Analyses of Mouse Pancreatic Endocrine Cells
Published on: September 30, 2018
The Chromatin Modifier MSK1/2 Suppresses Endocrine Cell Fates during Mouse Pancreatic Development
Neha Bhat1, Jeehye Park2, Huda Y Zoghbi2
1Institute for Regenerative Medicine, Department of Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania, Civic Center Blvd., Philadelphia, PA, United States of America.
Abstract:
Type I diabetes is caused by loss of insulin-secreting beta cells. To identify novel, pharmacologically-targetable histone-modifying proteins that enhance beta cell production from pancreatic progenitors, we performed a screen for histone modifications induced by signal transduction pathways at key pancreatic genes. The screen led us to investigate the temporal dynamics of ser-28 phosphorylated histone H3 (H3S28ph) and its upstream kinases, MSK1 and MSK2 (MSK1/2). H3S28ph and MSK1/2 were enriched at the key endocrine and acinar promoters in E12.5 multipotent pancreatic progenitors. Pharmacological inhibition of MSK1/2 in embryonic pancreatic explants promoted the specification of endocrine fates, including the beta-cell lineage, while depleting acinar fates. Germline knockout of both Msk isoforms caused enhancement of alpha cells and a reduction in acinar differentiation, while monoallelic loss of Msk1 promoted beta cell mass. Our screen of chromatin state dynamics can be applied to other developmental contexts to reveal new pathways and approaches to modulate cell fates.
Insights
Scientists identified MSK1/2 kinases as key regulators of pancreatic cell development. Inhibiting these kinases promotes beta cell production, offering a potential new strategy for treating Type I diabetes.
Area of Science:
- Developmental Biology
- Molecular Biology
- Endocrinology
Background:
- Type I diabetes results from the loss of insulin-producing beta cells.
- Identifying novel targets to enhance beta cell regeneration is crucial for diabetes treatment.
Purpose of the Study:
- To discover pharmacologically-targetable histone-modifying proteins that boost beta cell production from pancreatic progenitors.
- To investigate the role of histone modifications and their kinases in pancreatic cell fate determination.
Main Methods:
- Performed a screen for histone modifications at key pancreatic genes induced by signal transduction pathways.
- Investigated the temporal dynamics of serine-28 phosphorylated histone H3 (H3S28ph) and its kinases, MSK1 and MSK2 (MSK1/2).
- Utilized pharmacological inhibition and germline knockout of MSK1/2 in embryonic pancreatic explants and models.
Main Results:
- H3S28ph and MSK1/2 were found enriched at endocrine and acinar promoters in early pancreatic progenitors.
- MSK1/2 inhibition in embryonic explants promoted endocrine cell specification, including beta cells, and reduced acinar cell fates.
- Germline knockout of MSK1/2 enhanced alpha cells and reduced acinar differentiation; monoallelic loss of Msk1 increased beta cell mass.
Conclusions:
- The screen of chromatin state dynamics identified MSK1/2 as regulators of pancreatic cell fate.
- Pharmacological targeting of MSK1/2 shows potential for enhancing beta cell production and treating Type I diabetes.
- This approach can be applied to other developmental contexts to modulate cell fates.
More Related Videos
09:23Efficient Differentiation of Pluripotent Stem Cells to NKX6-1+ Pancreatic Progenitors
Published on: March 7, 2017
07:44Surgical Injury to the Mouse Pancreas through Ligation of the Pancreatic Duct as a Model for Endocrine and Exocrine Reprogramming and Proliferation
Published on: August 7, 2015
Related Concept Videos
Inheritance of Chromatin Structures
Cell Specific Gene Expression
Abnormal Proliferation
Master Transcription Regulators